RU2005133093A - Соединения для лечения флавивирусных инфекций - Google Patents
Соединения для лечения флавивирусных инфекций Download PDFInfo
- Publication number
- RU2005133093A RU2005133093A RU2005133093/04A RU2005133093A RU2005133093A RU 2005133093 A RU2005133093 A RU 2005133093A RU 2005133093/04 A RU2005133093/04 A RU 2005133093/04A RU 2005133093 A RU2005133093 A RU 2005133093A RU 2005133093 A RU2005133093 A RU 2005133093A
- Authority
- RU
- Russia
- Prior art keywords
- independently
- another
- hydrogen
- pharmaceutically acceptable
- optionally substituted
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims 44
- 150000001875 compounds Chemical class 0.000 title claims 10
- 206010057199 Flaviviral infections Diseases 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 150
- 239000001257 hydrogen Substances 0.000 claims 132
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 132
- 229910052794 bromium Inorganic materials 0.000 claims 72
- 229910052801 chlorine Inorganic materials 0.000 claims 72
- 239000003937 drug carrier Substances 0.000 claims 72
- 150000002148 esters Chemical class 0.000 claims 72
- 229910052731 fluorine Inorganic materials 0.000 claims 72
- 238000000034 method Methods 0.000 claims 70
- 208000015181 infectious disease Diseases 0.000 claims 60
- 125000002252 acyl group Chemical group 0.000 claims 54
- 125000000217 alkyl group Chemical group 0.000 claims 54
- 239000000651 prodrug Substances 0.000 claims 54
- 229940002612 prodrug Drugs 0.000 claims 54
- 150000003839 salts Chemical class 0.000 claims 54
- 230000001225 therapeutic effect Effects 0.000 claims 54
- 239000002777 nucleoside Substances 0.000 claims 48
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 44
- 229910052760 oxygen Inorganic materials 0.000 claims 42
- 229910052717 sulfur Inorganic materials 0.000 claims 42
- 239000002904 solvent Substances 0.000 claims 36
- 230000002265 prevention Effects 0.000 claims 35
- -1 β-D nucleoside Chemical class 0.000 claims 35
- 241000710781 Flaviviridae Species 0.000 claims 30
- 241000700605 Viruses Species 0.000 claims 30
- 230000002159 abnormal effect Effects 0.000 claims 27
- 230000004663 cell proliferation Effects 0.000 claims 27
- 201000010099 disease Diseases 0.000 claims 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 27
- 125000003342 alkenyl group Chemical group 0.000 claims 24
- 229940024606 amino acid Drugs 0.000 claims 24
- 150000001413 amino acids Chemical class 0.000 claims 24
- 125000003710 aryl alkyl group Chemical group 0.000 claims 24
- 125000003118 aryl group Chemical group 0.000 claims 24
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 24
- 239000001177 diphosphate Substances 0.000 claims 24
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 24
- 235000011180 diphosphates Nutrition 0.000 claims 24
- 125000000262 haloalkenyl group Chemical group 0.000 claims 24
- 125000001188 haloalkyl group Chemical group 0.000 claims 24
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 24
- 150000004712 monophosphates Chemical class 0.000 claims 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 24
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 24
- 239000001226 triphosphate Substances 0.000 claims 24
- 235000011178 triphosphate Nutrition 0.000 claims 24
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims 24
- 150000003904 phospholipids Chemical class 0.000 claims 23
- 239000003814 drug Substances 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 18
- 150000002367 halogens Chemical class 0.000 claims 18
- 238000004519 manufacturing process Methods 0.000 claims 18
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 18
- 229910052757 nitrogen Inorganic materials 0.000 claims 18
- 239000003085 diluting agent Substances 0.000 claims 17
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 12
- 229910052711 selenium Inorganic materials 0.000 claims 12
- 238000011321 prophylaxis Methods 0.000 claims 8
- ZZKNRXZVGOYGJT-VKHMYHEASA-N (2s)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 claims 5
- 239000002775 capsule Substances 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 238000007911 parenteral administration Methods 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- 230000000699 topical effect Effects 0.000 claims 3
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- RKZDOZOBLOFAIG-ZYLYKRSNSA-N C/C(/C(N)=O)=C(\C(\C(C12)(C1O)O[C@H](CO)C2O)=N/N)/O Chemical compound C/C(/C(N)=O)=C(\C(\C(C12)(C1O)O[C@H](CO)C2O)=N/N)/O RKZDOZOBLOFAIG-ZYLYKRSNSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45863503P | 2003-03-28 | 2003-03-28 | |
| US60/458,635 | 2003-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005133093A true RU2005133093A (ru) | 2006-07-27 |
Family
ID=33098273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005133093/04A RU2005133093A (ru) | 2003-03-28 | 2004-03-29 | Соединения для лечения флавивирусных инфекций |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20050049204A1 (enExample) |
| EP (1) | EP1626692A4 (enExample) |
| JP (1) | JP2006524227A (enExample) |
| CN (1) | CN1980678A (enExample) |
| AU (1) | AU2004224575A1 (enExample) |
| BR (1) | BRPI0408846A (enExample) |
| CA (1) | CA2529311A1 (enExample) |
| MX (1) | MXPA05010419A (enExample) |
| RU (1) | RU2005133093A (enExample) |
| WO (1) | WO2004084796A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| YU92202A (sh) | 2000-05-26 | 2006-01-16 | Idenix (Cayman) Limited | Metode i smeše za lečenje flavi virusa i pesti virusa |
| NZ537662A (en) | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| AU2003248748A1 (en) | 2002-06-28 | 2004-01-19 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| PT1576138T (pt) | 2002-11-15 | 2017-05-03 | Idenix Pharmaceuticals Llc | 2'-metil-nucleósidos em combinação com interferão e mutação de flaviviridae |
| RU2005121904A (ru) | 2002-12-12 | 2006-01-20 | Айденикс (Кайман) Лимитед (Ky) | Способ получения 2`-разветвленных нуклеозидов |
| WO2007047793A2 (en) * | 2005-10-19 | 2007-04-26 | University Of Georgia Research Foundation, Inc. | Cyclopentenol nucleoside compounds, intermediates for their synthesis and methods of treating viral infections |
| US20080182895A1 (en) * | 2006-08-25 | 2008-07-31 | Howe Anita Y M | Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto |
| WO2008067002A2 (en) * | 2006-09-11 | 2008-06-05 | Southern Research Institute | Azole nucleosides and use as inhibitors of rna and dna varial polymerases |
| KR101927905B1 (ko) * | 2008-04-03 | 2018-12-11 | 스프링 뱅크 파마슈티칼스, 인크. | 바이러스 감염증을 치료하기 위한 조성물 및 방법 |
| WO2009152589A1 (en) | 2008-06-17 | 2009-12-23 | Universidade Federal De Minas Gerais-Ufmg | Use of paf receptor for treating infections caused by flaviviridae |
| WO2014186435A2 (en) * | 2013-05-14 | 2014-11-20 | University Of Georgia Research Foundation, Inc. | Compositions and methods for reducing neointima formation |
| US20210353660A1 (en) * | 2018-10-04 | 2021-11-18 | Octagon Therapeutics Inc. | Pre-Activated Nucleoside IMPDH Inhibitors As Anti-Infective Drugs |
| WO2021110148A1 (zh) * | 2019-12-06 | 2021-06-10 | 南京明德新药研发有限公司 | siRNA缀合物、双链siRNA缀合物及其盐和应用 |
| US20230123911A1 (en) * | 2020-01-31 | 2023-04-20 | Octagon Therapeutics, Inc. | Modulation of immune cells |
| TWI879977B (zh) * | 2020-06-10 | 2025-04-11 | 大陸商正大天晴藥業集團股份有限公司 | 雙鏈siRNA類似物的共軛物 |
| CA3186763A1 (en) * | 2020-06-11 | 2021-12-16 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conjugate of double-stranded sirna analogue |
| WO2023155909A1 (zh) * | 2022-02-18 | 2023-08-24 | 南京明德新药研发有限公司 | 三氮唑核苷类似物及其作为嵌入基团的应用 |
| CN116808058A (zh) * | 2023-07-25 | 2023-09-29 | 徐州医科大学 | Pyrazofurin在制备治疗戊型肝炎疾病药物中的应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE29835E (en) * | 1971-06-01 | 1978-11-14 | Icn Pharmaceuticals | 1,2,4-Triazole nucleosides |
| US4211771A (en) * | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| US3798209A (en) * | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
| GB1414841A (en) * | 1972-02-11 | 1975-11-19 | Syntex Inc | 2,5-anhydro-dalloses derivatives thereof and c-glycosylnucleosides derived therefrom |
| US3960836A (en) * | 1974-07-22 | 1976-06-01 | Eli Lilly And Company | Acylated derivatives of pyrazofurin and process for their preparation |
| US5102883A (en) * | 1989-10-31 | 1992-04-07 | Du Pont Merck Pharmaceutical Company | Pyrimidine biosynthesis inhibitors useful as immunosuppressive agents |
| ZA931934B (en) * | 1992-03-18 | 1993-03-18 | Us Bioscience | Compostitions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals |
| GB9226729D0 (en) * | 1992-12-22 | 1993-02-17 | Wellcome Found | Therapeutic combination |
| US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
| PL187439B1 (pl) * | 1996-01-23 | 2004-07-30 | Icn Pharmaceuticals | Zastosowanie rybawiryny |
| US6150337A (en) * | 1996-01-23 | 2000-11-21 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes |
| US5767097A (en) * | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
| US20020137696A1 (en) * | 1996-01-23 | 2002-09-26 | Robert Tam | Specific modulation of TH1/TH2 cytokine expression by ribavirin in activated T-lymphocytes |
| US6509320B1 (en) * | 1996-10-16 | 2003-01-21 | Icn Pharmaceuticals, Inc. | Purine L-nucleosides, analogs and uses thereof |
| AU738170B2 (en) * | 1996-10-16 | 2001-09-13 | Icn Pharmaceuticals, Inc. | Monocyclic L-nucleosides, analogs and uses thereof |
| DE69729887T2 (de) * | 1996-10-16 | 2005-07-28 | ICN Pharmaceuticals, Inc., Costa Mesa | Purin-L-Nukleoside, Analoga und deren Verwendung |
| US6455690B1 (en) * | 1996-10-16 | 2002-09-24 | Robert Tam | L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine |
| NZ335000A (en) * | 1996-10-28 | 2000-12-22 | Univ Washington | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA |
| US6887707B2 (en) * | 1996-10-28 | 2005-05-03 | University Of Washington | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA |
| SK284520B6 (sk) * | 1997-12-22 | 2005-05-05 | Schering Corporation | Rýchlo sa rozpúšťajúci lisovaný ribavirínový prostriedok a spôsob jeho prípravy |
| US6423695B1 (en) * | 1998-01-13 | 2002-07-23 | Ribapharm, Inc. | Cytokine related treatments of disease |
| EA200700564A1 (ru) * | 1998-02-25 | 2007-08-31 | Эмори Юниверсити | 2`-фторнуклеозиды |
| CN1230198C (zh) * | 1998-05-15 | 2005-12-07 | 先灵公司 | 给首次接受抗病毒疗法的G慢性丙型肝炎感染患者施用包括利巴韦林和α干扰素的联合疗法 |
| US6833361B2 (en) * | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
| ES2229820T3 (es) * | 1998-10-16 | 2005-04-16 | Schering Corporation | Terapia de combinacion ribavirina-interferon alfa para erradicar el hcv-rna detectable en pacientes con infeccion por hepatitis c cronica. |
| MY125300A (en) * | 1999-02-26 | 2006-07-31 | Inst Of Molecular And Cell Biology | Synergistic combination for treatment of viral-mediated diseases |
| US6455508B1 (en) * | 2000-02-15 | 2002-09-24 | Kanda S. Ramasamy | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides |
| US6495677B1 (en) * | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
| US7056895B2 (en) * | 2000-02-15 | 2006-06-06 | Valeant Pharmaceuticals International | Tirazole nucleoside analogs and methods for using same |
| MXPA02008078A (es) * | 2000-02-18 | 2002-11-29 | Julio Javier Cristiani | Metodo para el tratamiento o prevencion de infecciones por flavivirus utilizando analogos de nucleosidos. |
| ATE414520T1 (de) * | 2000-04-13 | 2008-12-15 | Pharmasset Inc | 3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| YU92202A (sh) * | 2000-05-26 | 2006-01-16 | Idenix (Cayman) Limited | Metode i smeše za lečenje flavi virusa i pesti virusa |
| US6815542B2 (en) * | 2000-06-16 | 2004-11-09 | Ribapharm, Inc. | Nucleoside compounds and uses thereof |
| US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| CA2426187C (en) * | 2000-10-18 | 2011-08-16 | Pharmasset Limited | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation |
| JP2004533805A (ja) * | 2000-10-18 | 2004-11-11 | フアーマセツト・リミテツド | 疾患細胞中の核酸の多重定量 |
| CN1267446C (zh) * | 2001-01-22 | 2006-08-02 | 默克公司 | 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物 |
| US7105499B2 (en) * | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| GB0112617D0 (en) * | 2001-05-23 | 2001-07-18 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| WO2003026675A1 (en) * | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
| JP2005504087A (ja) * | 2001-09-28 | 2005-02-10 | イデニクス（ケイマン）リミテツド | ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物 |
| WO2003068162A2 (en) * | 2002-02-14 | 2003-08-21 | Pharmasset Ltd. | Modified fluorinated nucleoside analogues |
| AU2003248748A1 (en) * | 2002-06-28 | 2004-01-19 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| MXPA05001298A (es) * | 2002-08-01 | 2005-11-04 | Pharmasset Inc | Compuestos con el sistema biciclo[4.2.1] nonano para el tratamiento de infecciones por flaviviridae. |
| US20040067877A1 (en) * | 2002-08-01 | 2004-04-08 | Schinazi Raymond F. | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
-
2004
- 2004-03-29 US US10/812,448 patent/US20050049204A1/en not_active Abandoned
- 2004-03-29 MX MXPA05010419A patent/MXPA05010419A/es not_active Application Discontinuation
- 2004-03-29 JP JP2006506588A patent/JP2006524227A/ja active Pending
- 2004-03-29 EP EP04724085A patent/EP1626692A4/en not_active Withdrawn
- 2004-03-29 BR BRPI0408846-8A patent/BRPI0408846A/pt not_active IP Right Cessation
- 2004-03-29 RU RU2005133093/04A patent/RU2005133093A/ru not_active Application Discontinuation
- 2004-03-29 WO PCT/IB2004/001429 patent/WO2004084796A2/en not_active Ceased
- 2004-03-29 AU AU2004224575A patent/AU2004224575A1/en not_active Abandoned
- 2004-03-29 CN CNA2004800117467A patent/CN1980678A/zh active Pending
- 2004-03-29 CA CA002529311A patent/CA2529311A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05010419A (es) | 2006-05-31 |
| CN1980678A (zh) | 2007-06-13 |
| EP1626692A4 (en) | 2008-12-10 |
| EP1626692A2 (en) | 2006-02-22 |
| AU2004224575A1 (en) | 2004-10-07 |
| WO2004084796A3 (en) | 2006-04-06 |
| BRPI0408846A (pt) | 2006-07-04 |
| CA2529311A1 (en) | 2004-10-07 |
| US20050049204A1 (en) | 2005-03-03 |
| WO2004084796A2 (en) | 2004-10-07 |
| JP2006524227A (ja) | 2006-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005133093A (ru) | Соединения для лечения флавивирусных инфекций | |
| KR100598474B1 (ko) | 항종양제 | |
| MXPA05005379A (es) | Tioureas de arilo sustituidas y compuestos relacionados; inhibidores de duplicacion viral. | |
| JP2006524227A5 (enExample) | ||
| TW200600492A (en) | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | |
| JP2011525171A5 (enExample) | ||
| RU2011127079A (ru) | Комбинация производного циклоспорина и нуклеозидов для лечения инфекции вирусом гепатита с | |
| RU2008139195A (ru) | Замещенные арилсульфанамиды как противовирусные средства | |
| RU2007116858A (ru) | Тиазолилдигидроиндазолы | |
| RU2007102281A (ru) | 5-аза-7-деазапуриновые производные для лечения заболеваний, связанных с flaviviridae | |
| UA92746C2 (en) | Thiazole compounds and methods of use | |
| RU2006134005A (ru) | Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| RU2000102359A (ru) | Фармацевтическая композиция, обладающая улучшенным противораковым действием и/или сниженными побочными эффектами, содержащая противораковый агент и производное гидроксамовой кислоты | |
| US12325705B2 (en) | Small molecules for the treatment of primary cancer and cancer metastasis | |
| RU2010154173A (ru) | Режим введения нитрокатехолов | |
| RU2001113268A (ru) | Сочетанная терапия рибавирином и интерфероном α для удаления определяемой рнк вируса гепатита с у пациентов с хроническим гепатитом с | |
| HUP0500871A2 (hu) | 5-Ariltetrazol-vegyületek, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| KR101838764B1 (ko) | (ｅ)-4-카복시스티릴-4-클로로벤질설폰의 개선된 안정한 수성 제형 | |
| RU2002101622A (ru) | Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом | |
| ES2552734T3 (es) | Compuestos para usar en el tratamiento del cáncer | |
| RU2004126637A (ru) | Производные порфиринплатины, терапевтические активное соединение для получения средства для лечения опухолей, лекарственное средство и способ получения указанного средства | |
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
| RU2008138165A (ru) | Стероидные соединения в качестве ингибиторов стероидсульфатазы | |
| HUP0302629A2 (hu) | Camptotechin és sztilbénszármazékok kombinációját tartalmazó gyógyszerkészítmények rák kezelésére | |
| RU2001121195A (ru) | ((Аминоиминометил)амино)алканкарбоксидамиды и их применение в терапии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080312 |